BioLife Solutions, Inc. (BLFS)

17,54 -0,32 (-1,79%) Alla chiusura: 04:00PM EDT

BioLife Solutions, Inc.

3303 Monte Villa Parkway
Suite 310
Bothell, WA 98021
United States
425 402 1400
https://www.biolifesolutions.com

Settore/i: Healthcare
Settore: Medical Instruments & Supplies
Impiegati a tempo pieno: 409

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Roderick de Greef	CEO & Chairman	1,63M	N/D	1960
Mr. Troy Wichterman	Chief Financial Officer	485,2k	17,47k	1985
Ms. Karen Foster	Chief Quality & Operations Officer	395,2k	N/D	1960
Dr. Aby J. Mathew Ph.D.	Chairman of Scientific Advisory Board, Executive VP & Chief Scientific Officer	448,2k	2,68M	1972
Mr. Todd Berard	Chief Marketing Officer	286,49k	N/D	1969
Ms. Sarah Aebersold J.D.	Chief Human Resources Officer	N/D	N/D	1977
Mr. Garrie Richardson B.Sc., M.B.A.	Chief Revenue Officer	N/D	N/D	1973

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.

Governance aziendale

L'ISS Governance QualityScore di BioLife Solutions, Inc. al 29 aprile 2024 è 6. I criteri di valutazione fondamentali sono revisione: 10; Consiglio di Amministrazione: 7; diritti degli azionisti: 3; retribuzione: 5.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.